PODAXEF 325
Composition
Each Film-Coated Tablet Contains
- Cefpodoxime Proxetil USP
Equivalent to Anhydrous Cefpodoxime 100mg - Diluted Potassium Clavulanate BP
- Equivalent to Clavulanic Acid 62.5mg
- Exicipients q.s
Product Description
Podaxef combines cefpodoxime proxetil, an oral third-generation cephalosporin, with clavulanic acid, a potent β-lactamase inhibitor. This combination extends cefpodoxime’s spectrum to cover β-lactamase-producing organisms, providing reliable activity against a broad range of gram-positive and gram-negative pathogens responsible for community-acquired infections across multiple organ systems.
Dossage
Adults: 200mg cefpodoxime + 125mg clavulanic acid twice daily
Duration: 7–14 days depending on infection type and severity
Take with food to enhance absorption of cefpodoxime proxetil
Paediatrics: 10mg/kg/day cefpodoxime component divided twice daily
Dose adjustment required in renal impairment (eGFR <30)
Nafdac Reg
A4-100664
Indications
Cefpodoxime-Clav is indicated in the following infections when caused by suspectible organisms
Acute bacterial exacerbations of chronic bronchitis
Acute Community acquired Pneumonia
Upper and lower respiratory tract infections
Skin and soft tissue infections
Urinary Tract Infection
Pharyngitis and/or tonsilitis
General goborrhea (men and women) and Rectal gonococcal infections (women)
Acute maxillary sinustis
Direction for use
Therapeutic class
Antibiotics
Contracdiction`
Cefpodoxime Proxetil is contraindicated in patients with a known allergy to Cefpodoxime or to the cephalosporin group of antibiotics
Presentation
Tablets: 1 x 10’s Strip Pack
Side Effects
Side effects include bloody diarrhea, bloddy urine painful or difficult urination, unusual weakess, easy bleeding and bruising, confusion, fry mouth, increased urination, chills, body aches, fever, sore throat, headache, seizures, chest pain and irregular heart beat.
These side effects are very rare and do not affect a large amount of users.
Treatment should not normally exceed 14 days
PODAXEF 325
Product Description
Podaxef combines cefpodoxime proxetil, an oral third-generation cephalosporin, with clavulanic acid, a potent β-lactamase inhibitor. This combination extends cefpodoxime’s spectrum to cover β-lactamase-producing organisms, providing reliable activity against a broad range of gram-positive and gram-negative pathogens responsible for community-acquired infections across multiple organ systems.
Direction for use
Indications
Cefpodoxime-Clav is indicated in the following infections when caused by suspectible organisms
Acute bacterial exacerbations of chronic bronchitis
Acute Community acquired Pneumonia
Upper and lower respiratory tract infections
Skin and soft tissue infections
Urinary Tract Infection
Pharyngitis and/or tonsilitis
General goborrhea (men and women) and Rectal gonococcal infections (women)
Acute maxillary sinustis
Composition
Each Film-Coated Tablet Contains
- Cefpodoxime Proxetil USP
Equivalent to Anhydrous Cefpodoxime 100mg - Diluted Potassium Clavulanate BP
- Equivalent to Clavulanic Acid 62.5mg
- Exicipients q.s
Nafdac Reg
A4-100664
Dosage
Adults: 200mg cefpodoxime + 125mg clavulanic acid twice daily
Duration: 7–14 days depending on infection type and severity
Take with food to enhance absorption of cefpodoxime proxetil
Paediatrics: 10mg/kg/day cefpodoxime component divided twice daily
Dose adjustment required in renal impairment (eGFR <30)
Therapeutic class
Antibiotics
Contracdiction
Cefpodoxime Proxetil is contraindicated in patients with a known allergy to Cefpodoxime or to the cephalosporin group of antibiotics
Presentation
Tablets: 1 x 10’s Strip Pack
Side Effects
Side effects include bloody diarrhea, bloddy urine painful or difficult urination, unusual weakess, easy bleeding and bruising, confusion, fry mouth, increased urination, chills, body aches, fever, sore throat, headache, seizures, chest pain and irregular heart beat.
These side effects are very rare and do not affect a large amount of users.
Treatment should not normally exceed 14 days